Madrigal Pharma's liver disease drug succeeds in study, shares soar

(Reuters) - Madrigal Pharmaceuticals Inc said on Thursday its lead experimental drug achieved the main goal of reducing liver fat in patients with a type of liver disease in a mid-stage study, sending its shares surging 40 percent in premarket trading.

from Reuters: Health News https://ift.tt/2kF1Xmq